AR and pachyonychia congenita: Because the androgen receptor is a negative regulator of eIF4E phosphorylation at serine 209 [19,20], our new class of compounds can effectively inhibit Mnk/eIF4E in addition to AR transcriptional activity with the potential to negate negative feedback to prevent PC progression.